Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Amcenestrant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi trial failure halts work on breast cancer treatment amcenestrant
    Sanofi trial failure halts work on breast cancer treatment amcenestrant

    18 Aug 2022

    // Ludwig Burger REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-ends-development-amcenestrant-breast-cancer-treatment-2022-08-17/

    Ludwig Burger REUTERS
    18 Aug 2022
    Share Share
    Long wait for pivotal data on Sanofi's oral SERD ends in failure
    Long wait for pivotal data on Sanofi's oral SERD ends in failure

    15 Mar 2022

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/long-wait-pivotal-data-sanofis-oral-serd-ends-failure

    N.P. Taylor FIERCEBIOTECH
    15 Mar 2022
    Share Share
    Sanofi hit by filing delays for key drugs
    Sanofi hit by filing delays for key drugs

    29 Oct 2021

    // Ben Adams FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/sanofi-hit-by-filing-delays-for-key-drugs-drops-early-sangamo-thalassemia-asset

    Ben Adams FIERCEBIOTECH
    29 Oct 2021
    Share Share